A Second Look at Thor Halvorssen, President of the Human Rights Foundation Weasel Zippers A little over a month ago I took an unfair sharp jab at Thor Halvorssen, President of the Human Rights Foundation. He writes for the Huffington Post. Mr. Halvorssen, at the time, was sharply criticizing the British Royal Family for inviting some of the …
Glaxo, Human Genome Win Approval for 1st Lupus Drug in Years
GlaxoSmithKline Plc (GSK) and Human Genome Sciences Inc. (HGSI) won U.S. approval to sell Benlysta, a potential $3.6 billion product that will be the first new drug in 52 years for the auto-immune disease lupus.
www.StockMarketFunding.com (HGSI) Human Genome Sciences Benlysta Drug Approval for Lupus Patients. New Break through in Human Genome Sciences Benlysta drug approval for lupus patients. Will the Benlysta FDA Approval Come? We believe so at SMF and we will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in “biotechnology” in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies — antibodies that attack and destroy the body’s own healthy tissues. BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a …
Cloning is considered the great medical breakthrough of our age. As the definition says clones are copies of another humans look or what he/she likes to eat, but a persons whole personality is based on the experiences in his/her life and there is no method of cloning that can replace the personality. There are also medical disadvantages in human cloning, which make the benefits less effective. It was first thought that stem cells could only be harvested from embryos, but todays researchers are finding that any human cell can be manipulated to replace any tissue of the body. Health risks from mutation of genes – an abnormal baby would be a nightmare come true. The technique is extremely risky right now. A particular worry is the possibility that the genetic material used from the adult will continue to age so that the genes in a newborn baby clone could be – say – 30 years old or more on the day of birth. Many attempts at animal cloning produced disfigured monsters with severe abnormalities. So that would mean creating cloned embryos, implanting them and destroying (presumably) those that look imperfect as they grow in the womb. One of the manor Disadvantages of cloning is that there is a continuous debate relating to the ethical issue of cloning. The concept of cloning is hurting a lot of human sentiments ans human believes. There is a lot of controversy regarding whether cloning is ethical or not. at the present time the controversy is storming the world and took a great …
Complete video at: fora.tv A panel of DNA, policy, and research experts analyze the social implications of pharmaceutical companies and universities patenting the human genome. Ballon compares the argument against releasing genetic information to a 1961 study of cancer diagnosis. —– Personal genomic testing (the analysis of the DNA of individuals) is now available for less than $400. The consequences of personal genetic testing are often debated, with advocates arguing that genetic data can lead to improved health care and critics warning that consumers may be unduly worried upon learning results. California regulations impose conditions on firms providing personal genomic testing. This symposium examines genomic testing technology, its ramifications, government regulation of the industry, and whether individuals should have their genome analyzed. – Commonwealth Club of California Linda Avey has over 20 years of sales and business development experience in the biopharmaceutical industry in San Francisco, Boston, San Diego, and Washington, DC Prior to starting 23andMe, she developed translational research collaborations with academic and pharmaceutical partners for Affymetrix and Perlegen Sciences. Avey also spent time at Spotfire helping scientists understand the power of data visualization and at Applied Biosystems during the early days of the human genome project. The advent of high density genome-wide scanning technologies brought huge potential for significant …
www.myspace.com The private biotech firm Celera changed the rules of gene sequencing. The company’s so-called “shotgun” technique allowed Celera to sequence the entire genome in eight months — a feat that took the HGP several years to achieve. As its name suggests, however, the shotgun technique is less than meticulous. While the HGP’s traditional method kept track of where each decoded segment came from, Celera’s method required that all of the randomly separated pieces of the genome be painstakingly reassembled. This not-inconsequential step took Celera supercomputers another seven months to achieve. Even so, the total time it took the company to map the genome was faster than anyone could have imagined.
Oncolytics Biotech Harnesses Human Reovirus in Battle Against Colorectal Cancer
Enrollment for a Phase I study is open for patients with a form of colorectal cancer, where the patients will be treated with a cancer biologic called REOLYSIN
Global Human Vaccines Market to Reach US$25 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on Human Vaccines market.
www.StockMarketFunding.com Human Genome Sciences Benlysta Drug Approved for Lupus HGSI. FDA Approves Benlysta Human Genome Drug (HGSI) for Lupus Patients 50 Year Healthcare Development. Human Genome Sciences Benlysta Drug Approval HGSI FDA Panel. Tomorrow is the big day! We finally see how Human Genome Sciences Blockbuster Hopes on Lupus Drug Benlysta Pans Out based on Human Genome Sciences Benlysta® “FDA Panel Endorses a Drug to Treat Lupus” FDA Panel votes in favor of Benlysta stock expected to trade higher on Wednesday 17, 2010. FDA panel backs first new lupus drug in 50 years – Health News. Federal health experts on Tuesday voted in favor of the first new drug to treat Lupus in over 50 years. FDA Panel Recommends Approval Of Human Genome, Glaxo Lupus Drug. FDA Panel Endorses a Drug to Treat Lupus
Explorations this time examines the marvels and mysteries of the human mind and body. From brain implants to artificial intelligence, we explore the complexity and achievements of the human mind. From nanotechnology to biotechnology all in the name of medicine.
